MediSpend
The Director, Global Transparency is a senior leader responsible for the successful delivery, operational excellence, and strategic growth of Medispend's Global Transparency solutions and managed services. This role oversees customer delivery across software and services, ensuring accurate, timely, and compliant reporting while driving operational efficiency, customer satisfaction, and long-term client retention. The position provides leadership across Global Transparency Operations, Customer Success, and Delivery, partnering closely with Product, Engineering, Implementation, Regulatory Affairs, and Sales to deliver exceptional customer outcomes.
Headquarters
Portsmouth, New Hampshire, United States
Company Size
51-200 employees
Founded
2011
MediSpend provides commercial compliance software and client services that help life sciences companies grow their business compliantly. Their secure, scalable, cloud-based platform and professional services support pharmaceutical, medical device, dental and emerging biotech firms in managing commercial compliance. MediSpend serves more than 400 organizations worldwide, including large global pharma and medical device companies, with top-rated commercial compliance solutions.
MediSpend and Life Sciences Subsidiary of RLDatix Merge to Form Leading Global Provider of Regulatory and Compliance SaaS Solutions for Life Sciences
Sep 2, 2025
MediSpend Acquires Alucio to Expand AI-Enabled Stakeholder Engagement Capabilities
Aug 4, 2025
MediSpend, RLDatix Life Sciences merge to create new global compliance entity
Sep 8, 2025
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for MediSpend.
Susquehanna Growth Equity acquires majority share in MediSpend
Jun 3, 2021